Rituximabkezelés idiopathiás inflammatorikus myopathiákban

Translated title of the contribution: Rituximab therapy in idiopathic inflammatory myopathies

Levente Bodoki, Melinda Vincze, Zoltán Griger, Tamás Csonka, Karolina Cseri, Tibor Hortobágyi, Katalin Dankó

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Idiopathic inflammatory myopathies are systemic autoimmune diseases characterized by symmetrical weakness of proximal limb muscles. In the everyday practice it is not easy to treat idiopathic inflammatory myopathies. First-line therapy is based on corticosteroids. If there is no improvement in the symptoms and complaints in two months, a new immunosuppressant therapy has to be initiated. The aim of this summary is to present the biological agent rituximab in the therapy of this condition.

Original languageHungarian
Pages (from-to)16-21
Number of pages6
JournalLege Artis Medicinae
Volume23
Issue number1
Publication statusPublished - Mar 20 2013

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Bodoki, L., Vincze, M., Griger, Z., Csonka, T., Cseri, K., Hortobágyi, T., & Dankó, K. (2013). Rituximabkezelés idiopathiás inflammatorikus myopathiákban. Lege Artis Medicinae, 23(1), 16-21.